APG-115 in Salivary Gland Cancer Trial

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

October 28, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Malignant Salivary Gland CancerSalivary Gland Cancer
Interventions
DRUG

APG-115

APG-115 at 150mg (or lower, if dose is reduced) is taken orally every other day through day 13 of each cycle. Cycle length 21 days.

DRUG

Carboplatin

Carboplatin is given IV at AUC=4.5 on day 1 of each cycle. Cycle length 21 days.

Trial Locations (3)

33612

Moffitt Cancer Center, Tampa

48109

University of Michigan Rogel Cancer Center, Ann Arbor

60637

University of Chicago, Chicago

Sponsors
All Listed Sponsors
collaborator

Ascentage Pharma Group Inc.

INDUSTRY

lead

University of Michigan Rogel Cancer Center

OTHER

NCT03781986 - APG-115 in Salivary Gland Cancer Trial | Biotech Hunter | Biotech Hunter